TAZORAC

LOE Approaching

tazarotene

NDATOPICALCREAM
Approved
Sep 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
13

Mechanism of Action

Pharmacologic Class:

Retinoid

Clinical Trials (5)

NCT04720105Phase 4Completed

Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis

Started Nov 2020
NCT04071756Phase 2Terminated

Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions

Started Dec 2019
8 enrolled
Solid TumorHand-Foot Skin Reaction (HFSR)
NCT02849873Phase 1Completed

Absorption and Systematic Pharmacokinetics of IDP-123 Lotion in Comparison With Tazorac Cream

Started Jun 2016
NCT02938494Phase 2Completed

Safety and Efficacy of IDP-123 Lotion to Tazorac® Cream, in the Treatment of Acne Vulgaris

Started Nov 2015
NCT01119651Phase 1Completed

A Study to Evaluate the Potential of Tazarotene Foam to Cause an Allergic Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers.

Started Jun 2010
59 enrolled
Acne Vulgaris